The NCPE believe that, at the submitted price, brentuximab is not cost effective for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin Lymphoma who have failed at least one autologous stem cell transplant
The NCPE believe that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel
The NCPE consider this to be a cost effective product for the defined patient population in combination with psychosocial intervention.